Skip to main content
Premium Trial:

Request an Annual Quote

UK Sequencing Startup Becomes First International Competitor for Archon X Prize for Genomics

NEW YORK (GenomeWeb News) — UK-based start-up Base4 Innovation has become the first competitor from outside the US to participate in the Archon X Prize for Genomics, the X Prize Foundation said today.
 
The company is developing a new DNA sequencing method that combines “techniques such as photon detection and fluorescent labeling with nanostructures and cutting-edge methods of nanofabrication,” according to the foundation.  
 
Four other teams have entered the race, which will pay $10 million to the first team to sequence 100 human genomes in 10 days for less than $10,000 per genome. The teams are VisiGen Biotechnologies, 454 Life Sciences, the Foundation for Applied Molecular Evolution, and Reveo.
 
"This is an enormous, yet attainable challenge,” X Prize senior director Marc Hodosh said in a statement. “Such new technology will help mankind better understand disease while advancing proactive and preventative healthcare.”
 
Base4 is supported by the University of Warwick and Warwick Ventures, and includes a group of physicists and biologists from Oxford, Cambridge, and Warwick Universities, the foundation said.
The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.